Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
Medtronic plc director Scott C. Donnelly reported routine equity compensation activity. He received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted units vested, 207 shares were withheld at $81.90 per share to cover related tax obligations, rather than being sold on the market. Following these transactions, he directly holds 23,679 Medtronic ordinary shares, including 145 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Craig Arnold reported routine equity compensation activity involving the company’s ordinary shares. He received an award of 2,111 restricted stock units that vest on the one-year anniversary of the award date, increasing his direct holdings.
When previously granted restricted stock units vested, 207 shares were withheld to cover taxes, a non-market disposition used for tax payment rather than an open-market sale. Following these transactions, he directly owned 42,185 shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Medtronic PLC reports that Vanguard Capital Management beneficially owned 96,424,044 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole power to dispose of 96,424,044 shares and sole voting power for 13,090,211 shares. The disclosure attributes holdings to Vanguard Capital Management LLC and specified affiliates and was signed on 04/28/2026.
Medtronic plc reported that an unauthorized third party accessed data in certain corporate IT systems. After discovering the issue, the company contained the incident, activated its response protocols, and brought in external cybersecurity experts to investigate and remediate.
Medtronic states it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or its ability to meet patient needs. Based on current findings, it does not expect a material impact on its business or financial results. The company is assessing whether personal information was accessed and will notify and support affected individuals as needed.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A regarding Medtronic PLC common stock, reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Medtronic plc reported that its subsidiary MiniMed Group received earlier-than-expected U.S. FDA clearance for the MiniMed Flex, a next-generation, smartphone-controlled insulin pump. The product’s research and development was partly funded by Blackstone Life Sciences under a deal that entitles Blackstone to mid-to-high single digit royalties or specified minimum payments for two years after U.S. approval and launch.
MiniMed expects to record a one-time charge of $157 million in Medtronic’s fourth quarter of fiscal 2026 for future payments to Blackstone, with an estimated $0.08 per share impact based on Medtronic’s 90% MiniMed ownership. Separately, the recent IPO of 10% of MiniMed is expected to dilute Medtronic shareholders by about $0.04 per share in that quarter.
As a result, Medtronic now guides full-year fiscal 2026 non-GAAP EPS to $5.50–$5.54, reduced from the prior $5.62–$5.66 range. Guidance for fiscal 2027 remains unchanged at high single-digit EPS growth and is based on the earlier, higher EPS baseline before these MiniMed-related items.
Medtronic plc filed a shelf registration under Form S-3 to permit the periodic offering of debt securities by Medtronic Global Holdings S.C.A. and Medtronic, Inc., to be offered "from time to time after this registration statement becomes effective."
The prospectus states debt issued by each issuer will be fully and unconditionally guaranteed on a joint and several basis by the other group members named, and that specific terms, amounts and distribution methods will be provided in prospectus supplements.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.
On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.
Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.